talazoparib plus enzalutamide + Placebo plus enzalutamide
Phase 3Active 1 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Prostate Cancer
Conditions
Prostate Cancer
Trial Timeline
May 12, 2021 → Aug 28, 2027
NCT ID
NCT04821622About talazoparib plus enzalutamide + Placebo plus enzalutamide
talazoparib plus enzalutamide + Placebo plus enzalutamide is a phase 3 stage product being developed by Astellas Pharma for Prostate Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT04821622. Target conditions include Prostate Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Prostate Cancer were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
17
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04821622 | Phase 3 | Active |
Competing Products
20 competing products in Prostate Cancer